Hyperhidrosis is the excessive production of sweating, which can be primary and focal or secondary to various pathologies. The exact cause of primary focal hyperhidrosis is still unknown, although a genetic basis is recognized, and its prevalence varies from 1% to 2.8%. The most affected sites are the armpits, palms, soles and face. It causes much discomfort, affects the quality of life, and is estimated to be undervalued by health professionals. Many treatment options are proposed, both clinical and surgical. The aim of this review is to focus on the treatment of hyperhidrosis with oxybutynin, an anticholinergic drug originally used to control overactive bladder.
INTRODUCTION
Hyperhidrosis is characterized by an overproduction of
sweat, beyond what is necessary for thermal control. It is clinically divided in primary, of unknown cause, and secondary to several diseases, such as endocrine disorders, drugs, tumors and abnormalities of the nervous system. Primary hyperhidrosis is more common and is characterized by being symmetrical, most frequently reaching specified regions (mainly the axillary and palmar-plantar region),
with frequency of at least once a week, starting before 25 years of age, ceasing during sleep and having a familiar predisposition. 1 The cause of primary hyperhidrosis is not fully known, and it has been attributed to increased cholinergic stimulation, since studies show no hypertrophy or hyperplasia of the sweat glands. 2 A family history has been reported, supporting a genetic basis. 3 A large study with questionnaires applied to American families showed an incidence of hyperhidrosis in 6,800 individuals in a universe of 150,000 people surveyed, projecting a number of 7.8 million Americans with hyperhidrosis. Of these, 4 million present with axillary hyperhidrosis (1.4% of the American population). There was equivalence in the involvement of men and women. 4 In respect of quality of life, several studies show worsening in patients with primary hyperhidrosis. Studies report that the effects of hyperhidrosis are compared with more serious diseases such as severe psoriasis, renal failure at advanced stages, rheumatoid arthritis and multiple sclerosis. 5 Patients refer difficulties at work and decreased productivity, wasted time trying to control their disease, problems in relationships with friends and sexual relations, social phobia and difficulty with recreational activities, sports and manual and writing skills. 6 In addition to the psychosocial aspect, focal hyperhidrosis can increase the incidence of other skin diseases such as infections caused by fungi and bacteria, increased viral warts, eczematous lesions and bromhidrosis. 7 The diagnosis is eminently clinical and the first step is to differentiate between primary and secondary types, through anamnesis and clinical characteristics. Although we can try to quantify the perspiration through the iodine starch test, which consists in the application of 1% to 5% iodine solution sprinkled with starch to the affected areas. This solution, in the presence of perspiration, forms a characteristic purplish sediment. 1 Another objective method to quantify the sweating is the use of a non-invasive portable device with moisture sensors able to quantify the loss of transdermal water. 8 In addition, subjectively tests can be applied in the form of questionnaires, such as the severity scale of the hyperhidrosis-HDSS disease and the clinical protocol on the quality of life.
9,10
Treatment of hyperhidrosis is divided in clinical or surgical. Topical treatments (aluminum chloride and other metal salts) and glycopyrrolate are available. 11 Orally, there are anticholinergic agents like glycopyrrolate and methantheline that compete with muscarinic receptors. Of note, oxybutynin is one of the most used agents in clinical practice. Beta-blockers are also used to improve symptoms of social phobia and anxiety. Other described drugs are alpha adrenergic agonists such as clonidine, benzodiazepines, calcium channel blockers, propantheline, and gabapentin -all with few studies.
12,13
The botulinum toxin blocks the binding of acetylcholine and numerous other neurotransmitters in the presynaptic vesicles by temporary chemical denervation. 3 Its use can be conveyed both by iontophoresis or phonophoresis in an injectable manner. 3, 14 Apparatus for reducing hyperhidrosis include micronee-dling with fractionated radiofrequency, microwave, long-pulsed diode laser and 1064 nm Nd-YAG laser, and VASER ultrasound. 15 Regarding surgical treatment, there are local surgeries to attempt to remove glands such as skin resection of the axillary region, removal of subcutaneous tissue without excision of the skin and liposuction with curettage. 16 Another effective form of surgical treatment is video assisted thoracoscopy sympathetic blockade (sympathectomy), which can be accomplished by excision, ablation or clipping of the sympathetic chain. 17 The present study aims at conducting a literature review on the use of the anticholinergic agent oxybutynin for the treatment of hyperhidrosis.
METHOD
A literature search was performed in the United States National Library of Medicine databases (PubMed). The keywords used for the search were hyperhidrosis and oxybutynin. The research involved all scientific articles published until August 2015.
RESULTS
The first report using oxybutynin for hyperhidrosis occurred in 1988. 18 Later reports on the use of the drug in diabetic patients with gustatory sweating were published in an anecdotal manner. 19, 20 with an initial prescription of 2.5mg of oxybutynin every 8 hours.
Of these, eight patients had good results, three had to increase the dose to 5mg every 8 hours and three discontinued the medication because of adverse events. 26 Interesting studies in healthy subjects with hyperhidrosis induced by exercise showed no improvement with the use of oxybutynin (different mechanism of sweating?). 27, 28 But in other studies, the drug was effective in reducing perspiration induced by the use of anti-depressives, a frequent adverse event described with the use of these drugs.
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The second trial with a larger group of patients was conducted in Korea in 21 post-menopausal women with generalized hyperhidrosis. Oxybutynin 5mg was used in 19 women and 10mg daily in two patients, and all of them showed improvement and low adverse events rates.
31
A randomized study in women with persistent plantar hyperhidrosis after sympathectomy was performed including 16 patients receiving placebo and 16 receiving oxybutynin. An improvement was shown in both the questionnaire of quality of life as well as in the evaluation by Vapometer®. The maximum dose used was 10mg daily. Surprisingly, patients using placebo also improved, but at lower rates than those who took the drug. 32 In a French trial in which oxybutynin was used for generalized sweating in 30 patients (24 women and six men), starting with a low dose of 1.25mg and gradually increasing to a maximum dose of 7.5mg, the treatment was considered "very efficient" in 80% of the patients and "efficient" in 10%. The other three patients discontinued treatment because of complaints of adverse events. 33 Another Belgian study including nine patients using 7.5mg of oxybutynin showed improvement in palmar, but not in plantar hyperhidrosis. 34 Undoubtedly, the group with the highest number of cases and experience is Wolosker et al., who published several papers on the use of oxybutynin in large groups of patients for the treatment of hyperhidrosis in its various locations. [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] [45] [46] [47] [48] [49] [50] Following a standard protocol, they used a dose of 2.5mg per day in the first week, 5mg a day divided in two doses from day 8 up to day 42, and 10mg daily in two doses from day 43 up to day 84 (12 weeks). The method of assessing the response to treatment was always performed by questionnaires completed by patients. The first study, published in 2011 with 139 patients, showed improvement in palmar hyperhidrosis in more than 80% individuals and improvement in quality of life in 74.1%. The most frequent adverse event was dry mouth. 35 In another trial of 19 individuals with facial hyperhidrosis, most of them over 40 years old, the authors reported an overall improvement of 75%, with "great" improvement in 52%. 36 In a group with 82 patients with axillary hyperhidrosis, the improvement exceeded 70%, with "great" improvement in 36.3% and overall improvement in quality of life of 67.5%. 37 In 30 patients with plantar hyperhidrosis, 70% reported an overall improvement, and 66.6%
improved their quality of life. 38 In 20 patients treated with oxybutynin for hyperhidrosis of unusual sites (back or groin), 80% experienced improvement of their symptoms, and five patients interrupted treatment because of adverse events. 39 The same group published a placebo-control randomized study for the treatment of palmar and axillary hyperhidrosis. In 25 patients receiving placebo, 72.7% had no results after treatment, and in 25 patients receiving oxybutynin 73.9% refer relief of their symptoms. 40 When comparing the treatment outcome related to gender, there was no significant difference in improvement, with symptoms relief in about 70% in both groups. 41 Nor overweight or obesity was considered limiting factors for treatment, as 67.8% of patients with overweight and 63% obese showed significant clinical improvement. 42 When patients over 40 years were analyzed, 48 subjects between 40-49 years and 39 patients older than 50 years had significant improvement (75% in the first group and 87.2% in the second), with emphasis to the fact that most of the older patients had a high level of improvement. 43 At the other extreme, 45 children aged 7 to 14 years with palmar hyperhidrosis were evaluated, and over 85% showed improvement. Regarding the dose, patients with less than 40kg were treated with a maximum dose of 5mg daily, with two daily doses. 44 In respect to quality of life, improvement after treatment in relation to the pretreatment period was observed in 65.5% of patients rating "very poor" quality of life, and in 75% rating "poor" quality of life. 45 Regarding the treatment of compensatory hyperhidrosis after sympathectomy, in a recent study of 21 patients treated with oxybutynin, 71.4% reported improvement. Five patients discontinued treatment because of adverse events or lack of response. This study was conducted with a median follow-up of 337 days, longer than previous studies, most with 12 weeks. 46 Recently, this group has been publishing trials with longer follow-ups. In 397 patients with axillary hyperhidrosis, 114 did not improve and were referred to sympathectomy, eight had intolerable adverse events and 26 preferred surgery instead of medication use for long periods. On a mean follow-up of 17 months, 82.9% were improved, with better results in women. 47 The long term results in facial hyperhidrosis in 61 subjects showed maintenance in the improvement level experienced in the first 12 weeks in over 95% of the patients. 48 In the palmar hyperhidrosis, two did not improve and were directed to sympathectomy, eight patients had more significant adverse events, 30 did not want to continue using the drug for a long period and 111 did not prolong treatment after six months. Of the 246 patients with over six months of follow-up, 90.2% presented improvement. 49 In the plantar hyperhidrosis, out of 39 patients with follow-up longer than six months, all the women showed improvement in 84,7% of the cases (Chart 1). 50 In all reviewed papers, the most important adverse event present in approximately 70% of patients using the drug was dry mouth. Other events are rare and usually mild, but also contribute to the interruption of the medication administration. The main contraindication to the use of oxybutynin is the narrow-angle glaucoma (Chart 2). Tupker and col. 26 Kim and col. 31 Costa Jr and col. 32 Mailard and col. 33 Try and col. 34 Wolosker and col. 
CONCLUSIONS

